El-Battrawy, Ibrahim published the artcileImpact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article ‘Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics’, Product Details of C24H29N5O3, the publication is European Journal of Heart Failure (2022), 24(7), 1324, database is CAplus and MEDLINE.
A polemic in response to Jering et al is given. The article by Jering et al.1 published in this Journal presented an interesting study concept. The study group aimed to study the impact of sacubitril/valsartan treatment in comparison with ramipril on cardiovascular outcome in patients with acute myocardial infarction. Patients are included if left ventricular ejection fraction ≤40% and/or in case of pulmonary congestion.
European Journal of Heart Failure published new progress about 137862-53-4. 137862-53-4 belongs to amides-buliding-blocks, auxiliary class GPCR/G Protein,Angiotensin Receptor, name is (S)-2-(N-((2′-(1H-Tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid, and the molecular formula is C24H29N5O3, Product Details of C24H29N5O3.
Referemce:
https://en.wikipedia.org/wiki/Amide,
Amide – an overview | ScienceDirect Topics